Global vaccine patent applications hit a record high in the year to June 2025, according to data from intellectual property law firm Mathys & Squire. 

The total number of applications increased to 1220 from 1135 the previous year, a 7% increase on the previous year and a 129% increase on the number of applications in 2018/19. Patent applications for RNA vaccines now dominate the evolving patent thicket, increasing 31% to 449 in 2024/25, up from 344 the previous year.  

According to figures from Mathys & Squire, vaccine technology is moving away from traditional vaccines to more advanced technologies like DNA and RNA vaccines. Toxoid vaccines saw the sharpest drop in patent applications, with filings down 28% to 97 in 2024/25, from 134 the previous year and inactivated vaccines saw a 5% drop to 264, from 279 in 2023/24. 

Toxoid vaccine types, which use inactive toxins to prompt an immune response, like the tetanus vaccine, and subunit vaccines use proteins to trigger an immune response. These traditional vaccines are being replaced by safer, more versatile technologies such as mRNA vaccines. RNA vaccines work by delivering a small immune triggering part of the virus directly into a cell. 

The success of the Covid mRNA vaccine also shows that using newer, more agile technologies can deliver effective protection at a lower cost than conventional vaccines, according to Mathys & Squire. Traditional vaccines require expensive equipment and reagents and can be associated with safety and containment concerns. 

Despite the increase in patent applications, anti-vaccine comments from parts of Donald Trump’s administration could slow the development of vaccines. 

“Vaccine development is an expensive process,” said Martin MacLean, Partner at Mathys & Squire. “Mixed messaging from the (US) government could deter new investment – and therefore limit the number of new vaccines that can be developed and patented.” 

 

Bruno Quinney, Content Team, DDW